Imuprin

Azathioprine, the active ingredient in Imuprin, is an immunosuppressant presented as a tablet for oral use. It is used to prevent organ transplant rejection and to manage autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.

GNH USA supplies Imuprin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Azathioprine is employed in the management of several immune‑mediated conditions and in transplant prophylaxis.

- Organ transplantation prophylaxis: reduces the risk of acute graft rejection. - Rheumatoid arthritis: decreases joint inflammation and slows disease progression. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): helps maintain remission and lowers flare frequency. - Systemic lupus erythematosus: controls disease activity and prevents organ damage.

Azathioprine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea or vomiting. - Loss of appetite. - Mild leukopenia or neutropenia. - Rash or mild skin irritation. - Fatigue or general weakness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe bone‑marrow suppression leading to pancytopenia. - Hepatotoxicity with potential liver failure. - Acute pancreatitis. - Increased susceptibility to serious infections. - Higher long‑term risk of malignancies such as lymphoma. - Severe hypersensitivity reactions including Stevens‑Johnson syndrome.

Careful monitoring and patient education are essential when using azathioprine.

- Blood count monitoring: perform regular complete blood counts to detect leukopenia. - Liver function monitoring: assess hepatic enzymes periodically. - Pregnancy safety: avoid use in pregnancy unless benefits outweigh risks; category D. - Dose adjustments: modify dose in renal or hepatic impairment as advised by a clinician. - Infection risk: counsel patients to report signs of infection promptly. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Azathioprine interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Allopurinol: may cause severe bone‑marrow suppression. - TPMT deficiency (genetic): increases risk of toxicity; test before therapy.

Moderate Interactions (Monitor Closely): - Warfarin: azathioprine can enhance anticoagulant effect, requiring INR monitoring. - ACE inhibitors: may increase risk of neutropenia. - Live vaccines: reduced efficacy and potential infection risk. - NSAIDs: additive gastrointestinal irritation and bleeding risk.